Tuberculosis (TB) continues to be a serious public health problem despite global, national, and local strategies for its elimination. The World Health Organization (WHO) stated in its *Global Tuberculosis Report 2017* that during 2016 there were 10.4 million new cases of TB and that 1.68 million people died from this disease ([@B1]). In 2016, Colombia reported a total of 12 581 cases of TB. However, it is estimated that 3 000 people with the disease had not been diagnosed ([@B2]). In the city of Cali, Colombia, from January through December 2016, 106 deaths due to tuberculosis were reported, making up 10% of the total number of deaths in the city that year ([@B3]).

This mortality from TB could be related to a late diagnosis due to the lack of identification of people with respiratory symptoms, an inability of the health system to provide treatment once the patient is identified, and barriers to adherence to treatment ([@B4]). In Colombia, according to the national monitoring and evaluation guidelines, the period from the onset of symptoms to an early TB diagnosis should be less than 30 days ([@B5]). For the country overall, delays in TB diagnosis have been associated with patients being unemployed or internally displaced; with not having any health insurance; and with not having a contributive type of health insurance that is available to persons with a greater capacity to pay for health insurance ([@B6]).

In Brazil, a delay in seeking care has been shown to be associated with being a male between 18 and 29 years old ([@B7]). In Ethiopia, the delays in the diagnosis were not significantly different according to sex, but there was a greater topological delay among men, and patients with less education were more likely to present delays ([@B8]).

The city of Cali has 2 420 000 inhabitants and is located in southern Colombia. The city has a tuberculosis program that follows the national program standards, which are based on WHO recommendations. The program is implemented in both public and private less-complex health care institutions that receive periodic technical assistance and monitoring from the Cali TB control program, which in turn receives technical assistance from the National Institute of Health (INS) and the Ministry of Health in all that corresponds to TB guideline protocols and regulations.

In the early 1990s, Colombia launched a major health sector reform, which established a health insurance system with two main regimens: a subsidized one and one with contributive health care policies. Participants in the subsidized regimen represent the poorest and most vulnerable population, who are unable to pay the full health costs and thus require a total or partial subsidy to be able to receive health care services ([@B9]). Insurance under the contributive health care regime in Colombia is mandatory for people with an employment contract, pensioners or retirees, and self-employed persons with the capacity to pay to cover themselves and their family members ([@B10]).

In Cali, 15 to 20 cases of drug-resistant TB are diagnosed annually. The city is classified as a high-risk location for TB due to having a TB incidence level that is twice that of the nation overall. Approximately 90 to 100 people die each year from TB in Cali ([@B3]).

In 2015, health authorities in Cali pointed out to health care institutions and the community at large the delay in TB diagnosis. Those officials also established the goal that 80% of pulmonary TB cases would have an early diagnosis. However, the percentage of early TB diagnosis ranges between 60.0% and 67.0% ([@B2]). The objective of this study was to determine the risk factors associated with the delay in TB diagnosis and TB treatment initiation in pulmonary TB patients in Cali during the year 2016.

MATERIALS AND METHODS
=====================

Study design and setting
------------------------

We conducted a retrospective cohort study using records from Cali's TB control program from January through December 2016. For inclusion, individuals had to be more than one year old and have a diagnosis of pulmonary TB. In this study, pulmonary TB was identified as any patient that met the clinical or bacteriological diagnostic criteria. For clinical criteria, the patient had to present a positive clinical chart and positive radiology. The bacteriological criterion took into account the clinical chart and a positive sputum smear. Other criteria required for inclusion were being a resident of the urban area of Cali and the availability for this study of at least 80% of the study variables. Patients diagnosed with extrapulmonary TB or who had inconsistencies in their data or duplicate records were excluded.

Data collection
---------------

Information was collected from the databases of the Cali TB control program, individual treatment cards, and clinical charts. Data was entered into Microsoft Excel software with double entry to guarantee the quality of data, and then exported to Epi Info 7.1 software.

The outcome variables were the number of days from the onset of symptoms until TB diagnosis, and from TB diagnosis to TB treatment. Delay in TB diagnosis was defined as ≥ 30 days from the onset of respiratory symptoms to bacteriological confirmation of TB or radiological diagnosis. The variables considered were: 1) sociodemographic factors: sex, age, ethnic group (indigenous, mestizo, or Afro-descendant), health care workers, population groups with vulnerable conditions (homeless or displaced people, prisoners, persons with disabilities, pregnant women), type of health insurance affiliation; 2) clinical factors: coinfection with HIV, diabetes, and malnutrition; and 3) substance use (smoking and alcoholism). The health care service institution rating was also used. The rating was defined as the percentage of compliance with TB regulations, which was estimated during the rating technical assistance and included tuberculosis, information systems, and health care personnel. The rating ranged from 0% to 100%, classified as: 1) low adherence (less than 70%), 2) moderate adherence (70% to 80%), and 3) good adherence (\> 80%). In this study, pulmonary TB was defined as any patient admitted to the program as new, or previously treated, with a sputum smear-negative result, a positive culture, and a GeneXpert molecular test (GeneXpert is a cartridge-based amplification test of nucleic acid that is used for the rapid diagnosis of tuberculosis).

Data analysis
-------------

We performed a descriptive analysis of all the variables. The median and interquartile range (25th and 75th percentiles) were calculated in the following stages: 1) time in days from the time of the onset of respiratory symptoms to the diagnosis of TB; 2) time in days from the diagnosis of TB to the start of TB treatment; and 3) the total time in days from the onset of symptoms to the start of TB treatment. To explore which variables were associated with the time from of the onset of symptoms to TB diagnosis, a generalized linear model with a gamma distribution was used with an identity link function ([@B11]). For the variables included in the model, coefficients and their 95% confidence intervals were calculated using Stata version 11.0 software.

Ethical aspects
---------------

The study was approved by the Ethics Committee of the Universidad Pontificia Bolivariana (Medellín, Antioquia, Colombia) and the Ethics Review Committee of the Pan American Health Organization (Washington, D.C., United States of America). Written approval was also obtained from the Ministry of Public Health of the city of Cali.

RESULTS
=======

In 2016, 90 public and private health care institutions from all levels of care reported a total of 983 cases to the Cali tuberculosis program. Based on the eligibility criteria, 623 patients with pulmonary TB were included in the study. Among these 623 persons, 57.0% were male, the median age was 42 years (interquartile range (IQR): 27--60), 70.0% were between 15 and 60 years old, and 51.0% belonged to the subsidized health insurance program ([Table 1](#tbl01){ref-type="table"}).

One-third of the patients had sputum smear-negative TB (n = 195) ([Table 2](#tbl02){ref-type="table"}). Among the total number of sputum smear-negative TB individuals, 92 (47.0%) were reported as positive based on culture and 12 positive based on GeneXpert results (data not shown).

When analyzing the time between onset of symptoms and TB diagnosis, the median time found was 57 days (IQR: 21--117); it was longer in women than in men, in mestizos as compared to indigenous persons, and in people between 30 to 44 years old as compared to those older than 75 years. Regarding the total number of days between TB diagnosis and initiation of treatment, the median was 7 days (IQR: 2--17); it was longer in women than in men. The median total time from the onset of symptoms to the initiation of TB treatment was 72 days ([Table 1](#tbl01){ref-type="table"}).

Despite the fact that all the population groups had a delay in the diagnosis of TB (more than 30 days), the time periods were longer in the following groups: female, mixed race, 30 to 44 years old, subsidized health insurance, drug dependent, and malnourished ([Table 1](#tbl01){ref-type="table"}).

###### Sociodemographic characteristics and time from the onset of symptoms to diagnosis, from diagnosis to treatment initiation, and from onset of symptoms to treatment initiation in patients with pulmonary tuberculosis in Cali, Colombia, 2016 (N = 623)

  Characteristic                                      N/n                         \%    Days (median) between onset of symptoms and diagnosis (Q1, Q3)^[a](#TFN1){ref-type="table-fn"}^   Days (median) between diagnosis and initiation of treatment (Q1, Q3)   Total days (median) between onset of symptoms and treatment (Q1, Q3)   
  --------------------------------------------------- --------------------------- ----- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------
  Total                                               623                         100   57 (21--117)                                                                                      7 (2--17)                                                              72 (35--145)                                                           
  Sex                                                                                                                                                                                                                                                                                                                                   
                                                      Female                      267   43.0                                                                                              60 (26--103)                                                           7 (2--23)                                                              75 (40--125)
                                                      Male                        359   57.0                                                                                              51 (18--141)                                                           6 (2--13)                                                              68 (31--157)
  Ethnic group                                                                                                                                                                                                                                                                                                                          
                                                      Mestizo                     524   84.0                                                                                              59 (21--120)                                                           6 (2--17)                                                              73 (34--148)
                                                      Afro-Colombian              92    15.0                                                                                              50 (22--109)                                                           8 (4--16)                                                              73 (37--123)
                                                      Indigenous                  7     1.0                                                                                               36 (22--88)                                                            5 (0--7)                                                               41 (22--95)
  Age group in years                                                                                                                                                                                                                                                                                                                    
                                                      ≤ 14                        25    4.0                                                                                               45 (12--99)                                                            11 (5--72)                                                             91 (35--122)
                                                      15--29                      171   27.5                                                                                              50 (18--108)                                                           5 (2--12)                                                              65 (30--122)
                                                      30--44                      136   21.8                                                                                              67 (31--154)                                                           5 (2--12)                                                              80 (38--173)
                                                      45--59                      123   20.0                                                                                              55 (22--125)                                                           7 (2--17)                                                              64 (34--147)
                                                      60--74                      116   19.0                                                                                              58 (19--1110)                                                          10 (3--39)                                                             72 (36--150)
                                                      ≥ 75                        52    8.0                                                                                               35 (16--108)                                                           7 (3--27)                                                              66 (30--132)
  Population group                                                                                                                                                                                                                                                                                                                      
                                                      People incarcerated         37    6.0                                                                                               35 (22--90)                                                            4 (2--6)                                                               41 (26--104)
                                                      Pregnant women              3     0.4                                                                                               72 (13--86)                                                            4 (1--11)                                                              83 (14--90)
                                                      Displaced persons           12    2.0                                                                                               69 (36--89)                                                            8 (6--10)                                                              84 (65--99)
                                                      Persons with a disability   8     1.0                                                                                               69 (20--150)                                                           13 (1--33)                                                             88 (30--190)
                                                      Homeless persons            26    4.0                                                                                               70 (23--358)                                                           5 (0--12)                                                              77 (31--358)
                                                      Health care workers         12    2.0                                                                                               30 (8--116)                                                            10 (3--28)                                                             81 (31--139)
                                                      None of the above           525   84.0                                                                                              58 (21--117)                                                           7 (2--18)                                                              74 (36--145)
  Health insurance^[b](#TFN2){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                     
                                                      Contributory                249   40.0                                                                                              43 (17--118)                                                           6 (2--23)                                                              63 (30--155)
                                                      Subsidized                  318   51.0                                                                                              62 (26--116)                                                           7 (3--14)                                                              74 (38--139)
                                                      Without health insurance    56    9.0                                                                                               57 (28--122)                                                           6 (2--11)                                                              69 (38--140)
  Substance use                                                                                                                                                                                                                                                                                                                         
                                                      Drug dependence             76    12.0                                                                                              81 (31--179)                                                           5 (1--11)                                                              91 (38--187)
                                                      Smoking                     10    2.0                                                                                               80(17--411)                                                            9 (2--24)                                                              104 (23--494)
                                                      Alcoholism                  17    3.0                                                                                               80 (55--156)                                                           6 (2--14)                                                              118 (62--162)
                                                      No consumption              520   83.0                                                                                              52 (21--103)                                                           7 (2--18)                                                              70 (34--127)
  Clinical condition                                                                                                                                                                                                                                                                                                                    
                                                      HIV seropositive            46    7.4                                                                                               36 (13--80)                                                            4 (1--12)                                                              48 (31--98)
                                                      Diabetes                    57    9.2                                                                                               48 (21--87)                                                            2 (2--2)                                                               71 (38--104)
                                                      Malnutrition                72    11.6                                                                                              71 (26--146)                                                           5(1--13)                                                               80 (35--175)
                                                      No clinical condition       448   72.0                                                                                              58 (21--125)                                                           7 (3--18)                                                              75 (35--147)

***Source:*** Prepared by the authors, based on the study results.

Q1 = 25^th^ percentile; Q3 = 75^th^ percentile.

The subsidized health insurance regime represents the poorest and most vulnerable population, without the ability to pay for the insurance cost. The contributory health insurance regime is mandatory for people with an employment contract, retirees, and self-employed persons who are able to pay for the insurance cost.

###### Clinical characteristics and time in days from the onset of symptoms to diagnosis, from diagnosis to treatment initiation, and from onset of symptoms to treatment initiation in patients with pulmonary tuberculosis in Cali, Colombia, 2016 (N = 623)

  Characteristic                                  n                               Days between onset of symptoms and diagnosis, median (Q1, Q3)^[a](#TFN3){ref-type="table-fn"}^   Days between diagnosis and initiation of treatment, median (Q1, Q3)   Total days between onset of symptoms and treatment, median (Q1, Q3)   
  ----------------------------------------------- ------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------- --------------------------------------------------------------------- ---------------
  Admission condition                                                                                                                                                                                                                                                                                                          
                                                  New patient                     542                                                                                              54 (21--107)                                                          6 (2--28)                                                             71 (34--126)
                                                  Previously treated TB patient   81                                                                                               89 (26--353)                                                          7 (2--15)                                                             105 (38--381)
  Smear result^[b](#TFN4){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                
                                                  Positive +                      168                                                                                              55 (22--100)                                                          5 (2--9)                                                              61 (28--105)
                                                  Positive ++                     122                                                                                              58 (18--105)                                                          4 (1--8)                                                              65 (26--122)
                                                  Positive +++                    138                                                                                              68 (31--160)                                                          5 (2--10)                                                             73 (35--168)
                                                  Negative                        195                                                                                              48 (17--125)                                                          26 (6--53)                                                            94 (46--169)
  Culture result                                                                                                                                                                                                                                                                                                               
                                                  Positive                        280                                                                                              61 (23--127)                                                          8 (3--32)                                                             84 (43--153)
                                                  Negative                        140                                                                                              63 (21--132)                                                          7 (3--18)                                                             75 (31--179)
                                                  Not performed                   203                                                                                              45 (19--100)                                                          5 (1--10)                                                             53 (30--104)
  GeneXpert test result                                                                                                                                                                                                                                                                                                        
                                                  Detected                        107                                                                                              66 (27--142)                                                          5 (2--13)                                                             75 (38--64)
                                                  Not detected                    18                                                                                               24 (8--43)                                                            14 (5--43)                                                            54 (32--71)
                                                  Not interpretable               1                                                                                                67 (67--67)                                                           23 (23--23)                                                           90 (90--90)
                                                  Not performed                   273                                                                                              46 (18--103)                                                          6 (2--16)                                                             61 (30--136)
                                                  Not applicable                  224                                                                                              62 (24--122)                                                          7 (3--20)                                                             82 (39--142)

***Source:*** Prepared by the authors, based on the study results.

Q1 = 25^th^ percentile; Q3 = 75^th^ percentile.

The smear result refers to the number of bacilli identified by microscope: positive +: less than one bacillus per field is observed on average in 100 observed fields; positive ++: 1 to 10 bacilli are observed per field on average in 50 observed fields; positive +++: more than 10 bacilli are observed per field on average in 20 observed fields.

###### Risk factors associated with the time in days from the onset of symptoms to TB diagnosis and TB treatment initiation in patients with pulmonary tuberculosis in Cali, Colombia, 2016

  Variable                                                                  *P* value       Total time in days coefficient (95% CI)^[a](#TFN5){ref-type="table-fn"}^   TB treatment initiation coefficient (95% CI)^[b](#TFN6){ref-type="table-fn"}^   
  ------------------------------------------------------------------------- --------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------- -----------------------
  Constant                                                                  \< 0.001        111.6 (89.90 to 133.4)                                                     14.0 (9.11 to 18.90)                                                            
  Contributive health insurance plan                                        0.140           21.9 (−7.5 to 51.3)                                                        1.0 (−5.29 to 7.43)                                                             
  Person incarcerated                                                       0.001           −57.3 (−92.4 to −22.26)                                                    −7.3 (−13.9 to −7.31)                                                           
  Drug dependence                                                           0.320           24.1 (−23.6 to 72)                                                         −3.1 (−10.54 to 4.21)                                                           
  Health care worker                                                        0.200           −43.3 (−110.8 to 24)                                                       −3.3 (−23.60 to 16)                                                             
  Diabetes                                                                  0.080           −28.4 (−60.7 to 3.7)                                                       −3.2 (−11.15 to 4.57)                                                           
  Sex (female)                                                              0.720           −4.9 (−32.5 to 22.6)                                                       5.6 (−0.33 to 11.58)                                                            
  Previously treated TB patient                                             0.001           123.8 (48.3 to 199.3)                                                      14.0 (2.61 to 25.41)                                                            
  Health care service institution rating^[c](#TFN7){ref-type="table-fn"}^                                                                                                                                                                              
                                                                            70%--80%        0.080                                                                      52.5 (−7.5 to 112.5)                                                            14.8 (0.20 to 29.50)
                                                                            Less than 70%   0.670                                                                      68.3 (−252.5 to 389.3)                                                          3.0 (−41.66 to 47.77)

***Source:*** Prepared by the authors, based on the study results.

Total time in days from the onset of respiratory symptoms to TB treatment initiation, with 95% confidence interval (CI).

Time in days from TB diagnosis to TB treatment initiation.

The health care service institution rating is the percentage of compliance with regulations for tuberculosis, according to the rating technical assistance instrument.

More days elapsed from the onset of symptoms until the diagnosis in those patients who had been previously treated and in those with a negative culture ([Table 2](#tbl02){ref-type="table"}).

A factor associated with longer time from the onset of symptoms to TB treatment was being a previously treated TB patient. Being incarcerated was a protective factor for earlier TB treatment initiation ([Table 3](#tbl03){ref-type="table"}).

DISCUSSION
==========

This report is among the first attempts to determine the risk factors associated with delay in TB diagnosis and TB treatment initiation in pulmonary TB patients in the city of Cali. Our results show that despite all the global and national strategies and guidelines implemented by the Colombian TB program to identify people with respiratory symptoms, the median time between the onset of symptoms and TB treatment initiation in Cali was 72 days. Additionally, of the total number of patients included in the study (N = 623), 75.0% had ≥ 30 days between the onset of symptoms and treatment initiation. These findings highlight the important challenges that local TB programs have in achieving their goals, given that the maximum time between symptoms and treatment should 32 days (maximum of 30 days for TB diagnosis and 2 days for TB treatment initiation) ([@B3], [@B13]).

Research conducted in 2015 in Lima, Peru, to determine factors associated with diagnostic delay ([@B14]) found results similar to those in our study. In both Lima and Cali, the median time between onset of symptoms and the diagnosis was 57 days. In addition, when comparing the data by sex, the findings in Lima were similar to those in Cali, with the median delay in Lima being 62 days for women and 50 days for men.

Some studies conducted elsewhere in the world have reported a lower number of days between symptoms and TB treatment than what we found in Cali. This is the case for Brazil, with a median of 60 days ([@B13]); Ethiopia, with 70.5 days ([@B8]); and eight cities of Colombia, with a median of 51 days ([@B9]). On the other hand, some other studies have reported median delays of as much as 120 days ([@B6], [@B15], [@B16]).

The delay in the initiation of TB treatment in our Cali study is alarming, considering that this can lead to an increase in the spread of TB in the community. A total of 69% of the patients in Cali had a sputum smear-positive result, with 42% of the total with either a "++" or "+++" result ([Table 2](#tbl02){ref-type="table"}).

Of the Cali cases for which a molecular test such as GeneXpert was indicated, it was only performed in 65.0% of those patients. This finding shows the need to identify the possible barriers to accessing this molecular test, which can detect both TB and resistance to rifampicin ([@B18], [@B19]).

Medical care personnel can play a fundamental role in the late diagnosis of pulmonary tuberculosis. For example, beliefs associated with social stigma and insufficient knowledge about the disease---shared by the medical staff and patients---can contribute to the social construction of the stereotype of the disease and the patient. Those circumstances can reduce the chances of reaching an opportune diagnosis of pulmonary tuberculosis ([@B20]).

Even though we did not collect information on beliefs and knowledge of health staff in our Cali study, attendance at a health service institution that was rated between 70% and 80% on compliance with national TB program guidelines was a factor associated with delay in the initiation of tuberculosis treatment. This indicates the need for the TB program in Cali to reinforce adherence to national TB protocols and norms as well as to evaluate strategies and public policies related to TB diagnosis and early initiation of TB treatment.

Our data shows that previously treated patients had a greater delay in starting TB treatment---up to 123 days---as compared to recently admitted patients. A study conducted in India showed that the delay in TB diagnosis was 1.8 times higher among previously treated TB patients than in new TB cases ([@B20]), which is in line with our results. These differences in findings among the studies may be related to variations in the study populations, study settings, and socioeconomic backgrounds in the respective studies.

In our study, being incarcerated decreased the time of initiation to TB treatment up to 57 days in comparison with the general population. This could be explained by the reinforcement of TB control in prison in Cali and the characteristic of the TB program in this type of setting, where health care promoters and inmates affected by the disease have been trained to carry out active case findings of people with respiratory symptoms. It has been demonstrated that peer educators are effective participants in this process ([@B21]). Governmental commitment, partnerships, and sustained financing will be needed in order to continue these interventions in Cali.

Some factors should be taken into account when interpreting the results of this study. This was an operational study and therefore subject to the limitations of such research. We could only assess variables that are routinely collected in the registers, and there may be other factors related to delay that we were not able to assess. Furthermore, from the register reviews. we could not differentiate between patient-related delays and provider-related delays.

There were a number of noteworthy results in our study. One was the delay in diagnosis, with a median of 57 days. Another was that 25.0% of people will start treatment within 17 days after being diagnosed. A third was that the delay in diagnosis was greater in women, in people in the subsidized insurance regimen, and in people with some degree of malnutrition. A fourth was that were several factors associated with the delay in the diagnosis and the beginning of the treatment.

There are four important needed actions that this study has identified for the control of tuberculosis in the city of Cali. The first is to evaluate and update local TB program strategies and public policies related to TB diagnosis and early initiation of treatment. The second is to improve educational and health promotion activities in the Cali TB program, focusing them on patient delays. The third is to improve the efficiency of health care facilities by updating Cali\'s TB protocols, strengthening adherence to these reference documents, and training health care personnel. The fourth is to strengthen the links between health care institutions and the community.
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